In a market characterized by soaring valuations and heightened risk, three healthcare stocks stand out as attractive investment opportunities, trading at forward earnings multiples below 18. AstraZeneca, CVS Health, and Pfizer are all priced under $100 per share and present promising prospects for investors seeking value without excessive risk.
AstraZeneca, a U.K.-based pharmaceutical giant, is currently trading around $90 per share. The company has ambitious growth objectives, aiming to achieve $80 billion in annual revenue by 2030, bolstered by strategic acquisitions and investments. Over the last year, AstraZeneca generated $58.1 billion in sales and netted $9.4 billion in earnings. The stock has appreciated approximately 38% this year, reflecting strong market confidence. Notably, it boasts a forward price-to-earnings (P/E) ratio of just under 18, significantly lower than the S&P 500 average of 22, making it an appealing buy. Additionally, with a dividend yield of 1.7%, it provides investors with a return beyond capital appreciation.
CVS Health, the pharmacy and healthcare management company, has seen a remarkable upswing of over 70% in its stock price this year, yet it remains relatively undervalued at just under $80 per share. Following the appointment of CEO David Joyner last year, CVS has demonstrated solid performance, reporting an 8% revenue increase to $296.4 billion in the first nine months of 2025. The company recently improved its adjusted earnings per share forecast, now expected to range between $6.55 and $6.65 for the year. While CVS’s current P/E ratio exceeds 200 due to a recent goodwill impairment charge, its forward P/E of 11 sheds light on its more attractive valuation. With a dividend yield of 3.3%, significantly above the S&P 500 average, CVS healthily supports its status as a strong value investment.
Pfizer, trading at approximately $25 per share, has faced challenges this year, witnessing a 5% decline in stock price due to diminishing demand for its COVID-19 products. Despite this setback, the company forecasts sales of $62 billion for the year, only slightly down from last year’s nearly $64 billion. The stock’s forward P/E ratio is less than 9, making it one of the most affordable options in the current market. Analysts project a price target above $28, indicating potential upside of over 10% from its current valuation. Pfizer is actively shifting its focus away from pandemic-related products and is seeking growth through strategic acquisitions, such as its purchase of Metsera, which develops next-generation obesity therapies. With a robust dividend yield of 6.5%, Pfizer also presents an appealing choice for income-focused investors.
As investors navigate a challenging market landscape, AstraZeneca, CVS Health, and Pfizer offer compelling prospects for value-oriented portfolios, characterized by attractive valuations and strong growth potential.
